+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Huntington’s Disease Treatment Market - Global Forecast 2026-2032- Product Image
Huntington’s Disease Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Huntington’s Disease Treatment Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6138445
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Huntington’s Disease Treatment Market is projected to reach USD 3.52 Billion in 2026. It is expected to continue growing at a CAGR of 8.32%, reaching USD 5.68 Billion by 2032.

Huntington’s Disease Treatment: Executive Overview

Huntington’s disease is a progressive inherited neurodegenerative disorder caused by pathogenic expansion of the HTT gene. Treatment remains centered on symptom management, multidisciplinary care, genetic counseling, psychosocial support, and clinical research. Because disease expression and care needs vary considerably, effective management requires coordination across neurology, psychiatry, rehabilitation, nursing, social work, and family services.

Care Is Shifting Toward Earlier, Multidisciplinary Intervention

The treatment landscape is evolving from isolated symptom control toward longitudinal, patient-centered care. Greater use of genetic counseling, structured functional assessment, physical and occupational therapy, speech and swallowing support, nutrition management, and caregiver services is strengthening continuity across disease stages. Research activity is also emphasizing biomarkers, digital assessments, and interventions intended to modify disease biology, although clinical benefit, durability, safety, and regulatory acceptance require rigorous validation.

Artificial Intelligence Is Strengthening Diagnosis, Monitoring, and Research

Artificial intelligence may support Huntington’s disease care by identifying movement and speech changes, analyzing imaging or genetic data, improving remote monitoring, and helping researchers select participants and evaluate progression. These applications remain dependent on representative datasets, transparent validation, clinician oversight, privacy safeguards, and careful management of false positives and algorithmic bias. AI should augment-not replace-clinical judgment, genetic counseling, informed consent, and patient preferences.

Regional Insights: Uneven Access and Different Care Priorities

North America generally benefits from specialized movement-disorder services, research infrastructure, and established genetic counseling pathways, while access and insurance coverage remain uneven. Europe combines advanced referral networks with variation across national health systems and reimbursement arrangements. Asia-Pacific includes strong capabilities in countries such as Japan, South Korea, Australia, and China, alongside substantial differences in specialist availability and genetic testing access. Latin America faces gaps in diagnosis, specialist care, and affordability. The Middle East is expanding tertiary neurological services but experiences uneven referral capacity and genetic-counseling availability. Africa continues to face limited specialist coverage, diagnostic infrastructure, and sustained caregiver support, making decentralized education and integrated primary-care pathways important.

Group Insights: Policy Alignment and Cross-Border Coordination Matter

ASEAN countries face diverse health-system capacity, with opportunities to improve referral pathways, specialist training, and access to genetic services through regional cooperation. BRICS members span highly different levels of infrastructure and affordability, making adaptable treatment protocols and local research capacity important. The European Union benefits from collaborative research and cross-border policy mechanisms, although implementation differs among member states. G7 countries generally possess strong clinical and research capabilities but still must address affordability, aging caregivers, and equitable access. GCC health systems are investing in advanced specialist services while working to expand counseling and coordinated long-term care. NATO members represent varied health systems, but shared preparedness, rehabilitation expertise, and research collaboration can support continuity for affected families.

Country Insights: Capacity Varies Across Major Care Systems

Australia has established genetic and neurological services but must address geographic access. Brazil and Mexico continue to need broader specialist coverage, diagnostic pathways, and affordable multidisciplinary support. Canada and the United States have substantial expertise and research capacity, alongside regional, insurance, and caregiver-access disparities. China and India are expanding neurological capabilities, while diagnosis, genetic counseling, and rural access remain important priorities. Japan and South Korea have advanced clinical systems with growing emphasis on aging-related care coordination. France, Germany, Italy, Spain, and the United Kingdom offer structured neurological and rehabilitation services, although waiting times, regional variation, and long-term social-care integration remain relevant concerns. Russia faces the need to sustain specialist access, diagnostic support, and research connectivity across a geographically extensive system.

Priorities for Leaders: Build Coordinated, Evidence-Based Care Pathways

Industry and health-system leaders should strengthen multidisciplinary referral networks, expand genetic counseling and family support, and integrate rehabilitation, mental-health, nutrition, and palliative services into routine care. They should prioritize validated outcome measures, interoperable patient data, and ethically governed remote monitoring. Research programs should use inclusive recruitment, meaningful patient-centered endpoints, transparent safety monitoring, and long-term follow-up. Partnerships with clinicians, patient organizations, caregivers, and regulators can improve trial feasibility and ensure that emerging technologies address practical needs rather than adding complexity.

Research Methodology: Evidence-Based Synthesis of Clinical and System Factors

This executive summary uses a structured review approach focused on established clinical knowledge, treatment pathways, health-system considerations, and documented technology applications relevant to Huntington’s disease. Findings are synthesized across therapeutic management, diagnostics, rehabilitation, genetics, digital health, artificial intelligence, regional systems, and population-group contexts. Claims are framed qualitatively and are intended to distinguish established practice from emerging or investigational approaches; no market estimates, market shares, forecasts, or company-specific assessments are included.

Conclusion: Better Coordination Can Improve Huntington’s Disease Care

Huntington’s disease treatment is progressing through more coordinated symptom management, stronger genetic and family services, multidisciplinary rehabilitation, and research into disease-modifying approaches. The central challenge is translating scientific and digital advances into safe, accessible, and sustained care across diverse health systems. Leaders who invest in validated evidence, equitable referral pathways, caregiver support, and responsible innovation will be better positioned to improve outcomes and quality of life for affected individuals and families.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Huntington’s Disease Treatment Market, by Treatment Type
7.1. Introduction
7.2. Disease Modifying Therapies
7.2.1. Gene Silencing Therapies
7.2.2. Neuroprotective Therapies
7.3. Emerging Therapies
7.3.1. RNA Interference Therapies
7.3.2. Stem Cell Therapies
7.4. Symptomatic Therapies
7.4.1. Movement Disorder Treatments
7.4.2. Psychiatric Symptom Treatments
7.4.2.1. Depression Treatments
7.4.2.2. Psychosis Treatments
8. Huntington’s Disease Treatment Market, by Therapeutic Class
8.1. Introduction
8.2. Cell Based Agents
8.3. Gene Silencing Agents
8.4. Neuroprotective Agents
8.5. Neurotransmitter Modulators
9. Huntington’s Disease Treatment Market, by Delivery Mode
9.1. Introduction
9.2. Intrathecal
9.3. Intravenous
9.4. Oral
10. Huntington’s Disease Treatment Market, by End User
10.1. Introduction
10.2. Home Care Settings
10.3. Hospitals
10.4. Specialty Clinics
11. Huntington’s Disease Treatment Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Huntington’s Disease Treatment Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Huntington’s Disease Treatment Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Alnylam Pharmaceuticals, Inc.
15.2. AstraZeneca PLC
15.3. Azevan Pharmaceuticals Inc.
15.4. Bausch Health Companies Inc.
15.5. Biogen Inc.
15.6. Dr. Reddy’s Laboratories Ltd.
15.7. F. Hoffmann-La Roche Ltd
15.8. GlaxoSmithKline plc
15.9. H. Lundbeck A/S
15.10. Ionis Pharmaceuticals, Inc.
15.11. Neurocrine Biosciences, Inc.
15.12. Novartis AG
15.13. Pfizer Inc.
15.14. Prilenia Therapeutics B.V.
15.15. PTC Therapeutics Inc.
15.16. Sage Therapeutics Inc.
15.17. Sangamo Therapeutics, Inc.
15.18. Sanofi S.A.
15.19. Sun Pharmaceutical Industries Ltd.
15.20. Takeda Pharmaceutical Company Limited
15.21. Teva Pharmaceutical Industries Ltd.
15.22. uniQure N.V.
15.23. Vertex Pharmaceuticals Incorporated
15.24. Voyager Therapeutics, Inc.
15.25. Wave Life Sciences Ltd.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Huntington’s Disease Treatment Market, Years Considered for the Study
FIGURE 2. Global Huntington’s Disease Treatment Market, Research Design
FIGURE 3. Global Huntington’s Disease Treatment Market, Research Framework
FIGURE 4. Global Huntington’s Disease Treatment Market, Data Triangulation
FIGURE 5. Global Huntington’s Disease Treatment Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Huntington’s Disease Treatment Market Size, by Treatment Type, 2025 vs 2032 (%)
FIGURE 7. Global Huntington’s Disease Treatment Market Size, by Treatment Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2025 vs 2032 (%)
FIGURE 9. Global Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Huntington’s Disease Treatment Market Size, by Delivery Mode, 2025 vs 2032 (%)
FIGURE 11. Global Huntington’s Disease Treatment Market Size, by Delivery Mode, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Huntington’s Disease Treatment Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Huntington’s Disease Treatment Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Huntington’s Disease Treatment Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Huntington’s Disease Treatment Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Huntington’s Disease Treatment Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Huntington’s Disease Treatment Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Huntington’s Disease Treatment Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Huntington’s Disease Treatment Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Huntington’s Disease Treatment Market Segmentation & Coverage
TABLE 2. Global Huntington’s Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 3. Global Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 4. Global Disease Modifying Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Disease Modifying Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Disease Modifying Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Gene Silencing Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Gene Silencing Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Gene Silencing Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Neuroprotective Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Neuroprotective Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Neuroprotective Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Emerging Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Emerging Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Emerging Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global RNA Interference Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global RNA Interference Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global RNA Interference Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Stem Cell Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Stem Cell Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Stem Cell Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Symptomatic Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Symptomatic Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Symptomatic Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Movement Disorder Treatments Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Movement Disorder Treatments Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Movement Disorder Treatments Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Psychiatric Symptom Treatments Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Psychiatric Symptom Treatments Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Psychiatric Symptom Treatments Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Depression Treatments Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Depression Treatments Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Depression Treatments Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Psychosis Treatments Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Psychosis Treatments Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Psychosis Treatments Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 38. Global Cell Based Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Cell Based Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Cell Based Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Gene Silencing Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Gene Silencing Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Gene Silencing Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Neuroprotective Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Neuroprotective Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Neuroprotective Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Neurotransmitter Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Neurotransmitter Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Neurotransmitter Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 51. Global Intrathecal Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Intrathecal Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Intrathecal Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 61. Global Home Care Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Home Care Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Home Care Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Huntington’s Disease Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Huntington’s Disease Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 80. North America Huntington’s Disease Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. North America Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 82. North America Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 83. North America Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 84. North America Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 85. North America Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 86. North America Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 87. North America Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 88. North America Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. Latin America Huntington’s Disease Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Latin America Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 91. Latin America Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 92. Latin America Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 93. Latin America Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 94. Latin America Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 95. Latin America Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 96. Latin America Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 97. Latin America Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 98. Europe Huntington’s Disease Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Europe Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 100. Europe Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 101. Europe Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 102. Europe Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 103. Europe Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 104. Europe Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 105. Europe Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 106. Europe Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 107. Middle East Huntington’s Disease Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Middle East Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 109. Middle East Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 110. Middle East Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 111. Middle East Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 112. Middle East Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 113. Middle East Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 114. Middle East Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 115. Middle East Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 116. Africa Huntington’s Disease Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Africa Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 118. Africa Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 119. Africa Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 120. Africa Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 121. Africa Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 122. Africa Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 123. Africa Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 124. Africa Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 125. Global Huntington’s Disease Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. ASEAN Huntington’s Disease Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. ASEAN Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 128. ASEAN Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 129. ASEAN Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 130. ASEAN Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 131. ASEAN Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 132. ASEAN Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 133. ASEAN Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 134. ASEAN Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. GCC Huntington’s Disease Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. GCC Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 137. GCC Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 138. GCC Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 139. GCC Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 140. GCC Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 141. GCC Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 142. GCC Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 143. GCC Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 144. European Union Huntington’s Disease Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. European Union Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 146. European Union Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 147. European Union Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 148. European Union Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 149. European Union Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 150. European Union Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 151. European Union Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 152. European Union Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 153. BRICS Huntington’s Disease Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 154. BRICS Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 155. BRICS Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 156. BRICS Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 157. BRICS Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 158. BRICS Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 159. BRICS Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 160. BRICS Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 161. BRICS Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 162. G7 Huntington’s Disease Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 163. G7 Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 164. G7 Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 165. G7 Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 166. G7 Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 167. G7 Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 168. G7 Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 169. G7 Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 170. G7 Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. NATO Huntington’s Disease Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 172. NATO Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 173. NATO Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 174. NATO Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 175. NATO Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 176. NATO Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 177. NATO Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 178. NATO Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 179. NATO Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 180. Global Huntington’s Disease Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 181. United States Huntington’s Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 182. United States Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 183. United States Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 184. United States Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 185. United States Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 186. United States Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 187. United States Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 188. United States Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 189. United States Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 190. Canada Huntington’s Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 191. Canada Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 192. Canada Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 193. Canada Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 194. Canada Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 195. Canada Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 196. Canada Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 197. Canada Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 198. Canada Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. Mexico Huntington’s Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 200. Mexico Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 201. Mexico Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 202. Mexico Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 203. Mexico Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 204. Mexico Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 205. Mexico Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 206. Mexico Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 207. Mexico Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. Brazil Huntington’s Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 209. Brazil Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 210. Brazil Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 211. Brazil Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 212. Brazil Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 213. Brazil Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 214. Brazil Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 215. Brazil Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 216. Brazil Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 217. United Kingdom Huntington’s Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 218. United Kingdom Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 219. United Kingdom Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 220. United Kingdom Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 221. United Kingdom Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 222. United Kingdom Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 223. United Kingdom Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 224. United Kingdom Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 225. United Kingdom Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 226. Germany Huntington’s Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 227. Germany Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 228. Germany Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 229. Germany Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 230. Germany Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 231. Germany Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 232. Germany Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 233. Germany Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 234. Germany Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. France Huntington’s Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 236. France Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 237. France Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 238. France Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 239. France Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 240. France Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 241. France Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 242. France Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 243. France Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 244. Russia Huntington’s Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 245. Russia Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 246. Russia Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 247. Russia Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 248. Russia Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 249. Russia Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 250. Russia Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 251. Russia Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 252. Russia Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 253. Italy Huntington’s Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 254. Italy Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 255. Italy Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 256. Italy Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 257. Italy Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 258. Italy Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 259. Italy Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 260. Italy Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 261. Italy Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 262. Spain Huntington’s Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 263. Spain Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 264. Spain Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 265. Spain Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 266. Spain Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 267. Spain Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 268. Spain Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 269. Spain Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 270. Spain Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 271. China Huntington’s Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 272. China Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 273. China Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 274. China Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 275. China Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 276. China Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 277. China Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 278. China Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 279. China Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 280. India Huntington’s Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 281. India Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 282. India Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 283. India Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 284. India Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 285. India Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 286. India Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 287. India Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 288. India Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 289. Japan Huntington’s Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 290. Japan Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 291. Japan Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 292. Japan Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 293. Japan Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 294. Japan Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 295. Japan Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 296. Japan Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 297. Japan Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 298. Australia Huntington’s Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 299. Australia Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 300. Australia Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 301. Australia Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 302. Australia Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 303. Australia Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 304. Australia Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 305. Australia Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 306. Australia Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 307. South Korea Huntington’s Disease Treatment Market Size, 2017-2032 (USD Million)
TABLE 308. South Korea Huntington’s Disease Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 309. South Korea Huntington’s Disease Treatment Market Size, by Disease Modifying Therapies, 2017-2032 (USD Million)
TABLE 310. South Korea Huntington’s Disease Treatment Market Size, by Emerging Therapies, 2017-2032 (USD Million)
TABLE 311. South Korea Huntington’s Disease Treatment Market Size, by Symptomatic Therapies, 2017-2032 (USD Million)
TABLE 312. South Korea Huntington’s Disease Treatment Market Size, by Psychiatric Symptom Treatments, 2017-2032 (USD Million)
TABLE 313. South Korea Huntington’s Disease Treatment Market Size, by Therapeutic Class, 2017-2032 (USD Million)
TABLE 314. South Korea Huntington’s Disease Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 315. South Korea Huntington’s Disease Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 316. Global Huntington’s Disease Treatment Market Share,

Companies Mentioned

  • Alnylam Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Azevan Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • Biogen Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • F. Hoffmann‑La Roche Ltd
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Ionis Pharmaceuticals, Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Prilenia Therapeutics B.V.
  • PTC Therapeutics Inc.
  • Sage Therapeutics Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • uniQure N.V.
  • Vertex Pharmaceuticals Incorporated
  • Voyager Therapeutics, Inc.
  • Wave Life Sciences Ltd.

Related Reports

Huntington Disease Medications Market - Global Forecast 2026-2032 - Product Image

Huntington Disease Medications Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Huntington`s Disease Therapeutics Market - Global Forecast 2026-2032 - Product Image

Huntington`s Disease Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Huntington's Disease - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Huntington's Disease - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 198 Pages
  • Global
From
Huntington's Disease Treatment Market Size, Share, Trends and Forecast by Type, Drug Type, Age, Distribution Channel, End User, and Region, 2026-2034 - Product Image

Huntington's Disease Treatment Market Size, Share, Trends and Forecast by Type, Drug Type, Age, Distribution Channel, End User, and Region, 2026-2034

  • Report
  • 142 Pages
  • Global
From
Huntington's Disease Market Report 2026 - Product Image

Huntington's Disease Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.